Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses.
Small molecules that bind to normally unoccupied thyroxine (T(4)) binding sites within transthyretin (TTR) in the blood stabilize the tetrameric ground state of TTR relative to the dissociative transition state and dramatically slow tetramer dissociation, the rate-limiting step for the process of amyloid fibril formation linked to neurodegeneration and cell death. These so-called TTR kinetic stabilizers have been designed using structure-based principles and one of these has recently been shown to halt the progression of a human TTR amyloid disease in a clinical trial, providing the first pharmacologic evidence that the process of amyloid fibril formation is causative. Structure-based design has now progressed to the point where highly selective, high affinity TTR kinetic stabilizers that lack undesirable off-target activities can be produced with high frequency.
Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. connelly@scripps.edu
Stephen
S
Connelly
Sungwook
S
Choi
Steven M
SM
Johnson
Jeffery W
JW
Kelly
Ian A
IA
Wilson
D000686:Amyloidosis / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D015195:Drug Design; D006801:Humans; D007700:Kinetics; D011228:Prealbumin / Q000737:chemistry* / Q000378:metabolism*; D055550:Protein Stability / Q000187:drug effects; D013974:Thyroxine / Q000378:metabolism
D011228:Prealbumin; D013974:Thyroxine